...
首页> 外文期刊>Toxicology Research >Pseudo-allergic reaction caused by Qingkailing injection partially via the PI3K-Rac1 signaling pathway in RBL-2H3 cells
【24h】

Pseudo-allergic reaction caused by Qingkailing injection partially via the PI3K-Rac1 signaling pathway in RBL-2H3 cells

机译:通过RBL-2H3细胞的PI3K-RAC1信号通路部分通过PI3K-RAC1信号通路引起的假过敏反应

获取原文
获取原文并翻译 | 示例
           

摘要

Qingkailing injection (QKLI) is a kind of multi-component traditional Chinese medicine injection. It has been widely used in clinical practice, but in recent years, it has caused more and more adverse reactions, mainly manifested as pseudo-allergic symptoms. To explore the potential mechanism of the pseudo-allergic reaction by QKLI, basophilic leukemia cell line 2H3 (RBL-2H3) was chosen. The results showed that QKLI at doses of 5, 10 and 20 mL L-1 activated phosphoinositide 3-kinase (PI3K) activity and also increased the levels of Ras-related C3 botulinum toxin substrate 1 (Rac1), p21 protein-activated kinase 1 (Pak1), LIM kinase (Limk1) and cofilin (an actin polymerization regulator) proteins. What's more, QKLI aggravated the depolymerization of F-actin. NSC23766, a Rac1 inhibitor, reversed the previous results in QKLI-treated RBL-2H3 cells. In addition, when the Rac1 gene was knocked down using lentiviral vector-loaded shRNA in RBL-2H3 cells, the PI3K activity and depolymerization of F-actin were downregulated, hinting that the pseudo-allergic reaction was significantly reduced. In general, the pseudo-allergic reaction induced by QKLI was likely to be based on PI3K-Rac1 signaling pathways partially.
机译:清滑注射(QKLI)是一种多组分中药注射。它已被广泛应用于临床实践,但近年来,它引起了越来越多的不良反应,主要表现为假过敏症状。为了探讨QKLI伪过敏反应的潜在机制,选择嗜碱性白血病细胞系2H3(RBL-2H3)。结果表明,QKLI为5,10和20mL L-1活化磷酸阳性3-激酶(PI3K)活性,也增加了RA相关的C3肉毒杆菌毒素底物1(RAC1),P21蛋白活化激酶1的水平。 (PAK1),LIM激酶(LIMK1)和COFILIN(肌动蛋白聚合调节剂)蛋白。更重要的是,Qkli加剧了F-actin的解聚。 NSC23766,RAC1抑制剂,逆转QKLI处理的RBL-2H3细胞中的先前结果。另外,当使用RBL-2H3细胞中的慢病毒载体加载的ShRNA敲击RAC1基因时,下调F-actin的PI3K活性和F-Actin的解聚,暗示伪过敏反应显着降低。通常,QKLI诱导的伪过敏反应可能部分地基于PI3K-RAC1信号传导路径。

著录项

  • 来源
    《Toxicology Research》 |2019年第3期|共8页
  • 作者单位

    Zhejiang Acad Med Sci Inst Mat Med Key Lab Neuropsychiat Drug Res Zhejiang Prov Hangzhou 310013 Zhejiang Peoples R China;

    Zhejiang Acad Med Sci Inst Mat Med Key Lab Neuropsychiat Drug Res Zhejiang Prov Hangzhou 310013 Zhejiang Peoples R China;

    Zhejiang Acad Med Sci Inst Mat Med Key Lab Neuropsychiat Drug Res Zhejiang Prov Hangzhou 310013 Zhejiang Peoples R China;

    Zhejiang Acad Med Sci Inst Mat Med Key Lab Neuropsychiat Drug Res Zhejiang Prov Hangzhou 310013 Zhejiang Peoples R China;

    Zhejiang Acad Med Sci Inst Mat Med Key Lab Neuropsychiat Drug Res Zhejiang Prov Hangzhou 310013 Zhejiang Peoples R China;

    Zhejiang Acad Med Sci Inst Mat Med Key Lab Neuropsychiat Drug Res Zhejiang Prov Hangzhou 310013 Zhejiang Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号